In one randomized controlled trial of two patients, baricitinib was used in one patient with PBC who had inadequate response to UDCA, which showed 30% decrease in ALP level, 7‐point improvement in itch NRS, and improvement in marker of inflammation (CRP) and liver fibrosis score over a 12‐week period [4]. This evidence concerns the gene CRP and primary biliary cholangitis.